Michael R. Bishop
迈克尔·毕晓普
MD
Professor of Medicine; Director, Hematopoietic Cellular Therapy Program医学教授；造血细胞治疗项目主任
👥Biography 个人简介
Dr. Michael R. Bishop is a leading expert in CAR-T cell therapy for aggressive B-cell lymphomas. He was a principal investigator in the ZUMA-1 pivotal trial of axicabtagene ciloleucel (axi-cel) for relapsed/refractory DLBCL, which established CAR-T as a standard-of-care option.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ZUMA-1 Trial Leadership
Served as key investigator in the landmark ZUMA-1 trial demonstrating durable remissions with axi-cel CAR-T in relapsed/refractory DLBCL, leading to FDA approval and transforming treatment paradigms.
Representative Works 代表性著作
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine (2017)
Pivotal ZUMA-1 results showing 54% objective response rate with axi-cel in refractory DLBCL, establishing CAR-T as a viable salvage therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Carl H. June
University of Pennsylvania
Michel Sadelain
Memorial Sloan Kettering Cancer Center
Crystal L. Mackall
Stanford University
Katy Rezvani
MD Anderson Cancer Center
关注 迈克尔·毕晓普 的研究动态
Follow Michael R. Bishop's research updates
留下邮箱，当我们发布与 Michael R. Bishop（University of Chicago Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment